WVU Medicine Princeton Community Hospital pairs up with WVU Medicine Children's to strengthen pediatric care
According to a press release, the family-friendly event will afford the community a chance to meet staff members that care for children in the area and discover more about the affiliation's offerings.
Strawberry Festival prepares return to Alderson in 2025
Guests of the event can partake in giveaways, demonstrations, games, face painting, and more. Entertainment will be provided in the form of a performance from the PikeView Marching band, the release stated. Atlas, the WVU Medicine Children's therapy dog will also be in attendance.
We are excited to invite families in the community to see firsthand the incredible pediatric services now available through our partnership with WVU Medicine Children's. This event is a celebration of our continued commitment to providing compassionate, expert care for children and families throughout southern West Virginia.
Karen Bowling | President and CEO, WVU Medicine Princeton Community Hospital
'Chalk the Walk' gives an artistic spin to a sensitive subject
The partnership allows for access to high-quality children's care closer. Patients will also have access to expanded services with one of the nation's leading hospitals for kids.
Families will also have the comfort of knowing their child's care team is backed by the expertise and resources of WVU Medicine Children's, the release noted. This includes chances to be involved in clinical research, shared safety standards, and coordinated care.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10-07-2025
- Yahoo
Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD
Advancing corrector and potentiator programs to address underlying biology of autosomal dominant polycystic kidney disease (ADPKD) across multiple mutations Team includes preeminent scientific leaders in ADPKD; rapid discovery and development efforts powered by suite of proprietary assays $54.5 million in seed financing led by founding investor 5AM Ventures alongside Atlas Venture, OrbiMed and Qiming Venture Partners USA BERKELEY, Calif., July 10, 2025--(BUSINESS WIRE)--Renasant Bio (Renasant), announced its launch today to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is developing a pipeline of oral small molecule corrector and first-in-class potentiator therapies that directly target the underlying biology of ADPKD, with the goal of restoring the function of key polycystin proteins across multiple different mutations to halt disease progression. Renasant has raised $54.5 million in seed funding, co-led by founding investor 5AM Ventures, alongside other leading life sciences investors including Atlas Venture, OrbiMed and Qiming Ventures. The seed financing will support further progression of Renasant's lead corrector program and ongoing discovery efforts for the company's first-in-class potentiator program. "ADPKD is a devastating genetic disorder that affects more than 12 million people globally and still lacks truly disease-modifying therapies," said Emily Conley, Ph.D., chief executive officer of Renasant. "Our platform of differentiated correctors and first-in-class potentiator therapies are designed to directly address the underlying cause of ADPKD across its broad mutation spectrum, offering the potential to benefit the vast majority of patients." Next-Generation Corrector and Potentiator Programs for ADPKD Autosomal Dominant Polycystic Kidney Disease (ADPKD) Autosomal dominant polycystic kidney disease is a chronic, progressive genetic condition marked by the progressive formation of fluid-filled cysts in the kidneys, often leading to end-stage renal failure. The condition arises from mutations in the PKD1 and PKD2 genes, which encode polycystin proteins PC1 and PC2—critical regulators of kidney cell function. The genetic mutations underlying ADPKD are extremely heterogeneous, with no single mutation found in more than 2% of patients. Disease-modifying strategies that correct or potentiate polycystin biology must overcome this diversity—making therapies that work broadly across mutations a key treatment advancement for ADPKD. Current therapies do not directly address the underlying protein dysfunction and are limited in their applicability and tolerability. Addressing the Underlying Biological Drivers of ADPKD Renasant's therapeutic strategy is centered on restoring the normal function of PC1 and PC2. Through its leading expertise in ADPKD biology, including electrophysiology and polycystin channel physiology, Renasant has developed proprietary assays to assess protein trafficking and other key mechanisms, enabling precision-guided development of novel therapies for ADPKD. The company's lead program is a small molecule corrector designed to work across a wide range of disease-causing mutations to stabilize and properly fold PC1/2, promoting protein trafficking to restore kidney function. The program is currently progressing through preclinical development. In addition, Renasant is advancing discovery efforts toward a potentiator to enhance ion flux through the polycystin channel and support anti-cystogenic signaling—a first-in-class approach in ADPKD. Correctors and potentiators can act as stand-alone therapies, or they can be combined for synergistic effect. "Our corrector program is designed to work across a broad range of mutations, and our potentiator represents a novel mechanism of action in ADPKD," said Gus Gustafson, Ph.D., chief scientific officer. "These programs hold the potential to reshape the treatment landscape. We are very encouraged by our preclinical data and committed to rapidly advancing these programs for patients in urgent need." Team of Leading Experts in ADPKD Renasant is led by a world-class team with deep expertise in ADPKD biology and a proven track record in building biopharma companies. The team includes researchers who have shaped the field of polycystin biology and electrophysiology, seasoned drug developers, and biotech executives experienced in advancing cutting-edge scientific approaches. "5AM Ventures founded Renasant around a bold idea: that we could change the trajectory of ADPKD," said Deborah Palestrant, Ph.D., partner at 5AM Ventures. "ADPKD is one of the most complex diseases in renal medicine, but Renasant has assembled the right team, with years of research experience in polycystic disease that has informed the right scientific approach. We're proud to have supported the company from the start and are energized by its progress and commitment to delivering truly disease-modifying treatments for ADPKD patients." Renasant's executive team includes: Emily Conley, Ph.D., chief executive officer Gus Gustafson, Ph.D., chief scientific officer B. Barry Touré, Ph.D., senior vice president, drug discovery Rachel Gallagher, Ph.D., vice president, biology Michelle Ho Huey, Ph.D., vice president, strategy & operations Renasant's board of directors includes: Natalie Holles, chair of the board Kevin Bitterman, Ph.D., partner, Atlas Venture Evan Caplan, M.D., principal, OrbiMed Emily Conley, Ph.D., chief executive officer Anna French, D. Phil, managing partner, Qiming Venture Partners USA Charlotte McKee, M.D., chief medical officer, Sionna Therapeutics Deborah Palestrant, Ph.D., partner, 5AM Ventures In addition, Renasant has assembled a scientific advisory board consisting of preeminent leaders in ADPKD genetics, biology, and both preclinical and clinical drug development. About Renasant Bio Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression. Renasant was founded by and incubated within the 4:59 Initiative, the company creation engine of 5AM Ventures, and is based in Berkeley, California. For more information, please visit us at and follow us on LinkedIn and X. View source version on Contacts Media Katie Engleman1ABkatie@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
18-06-2025
- CBS News
Puppy found suffering from heatstroke in hot car prompts warning from Beaver County Humane Society
A puppy suffering from heatstroke was rescued from a car in Hopewell Township, prompting a warning from the Beaver County Humane Society. Last week, a 6-month-old Doberman named Atlas was found by Hopewell Township police in "extreme heat-related stress," locked in a car with a stopped engine and no access to water. Humane officers said Atlas had been locked inside for nearly 30 minutes before he was rescued, and when he got to the shelter, he was "dangerously" dehydrated, weak and trembling. After the team at the humane society stabilized Atlas, he was taken to an emergency vet for overnight hospitalization. He was surrendered by his owner, and while he's in stable condition and recovering, the humane society says Atlas isn't out of the woods yet. He's made significant improvements in the past week, but the shelter doesn't know the full extent of the injuries caused by his prolonged exposure to extreme heat. Humane society warns of leaving pets in hot cars The Beaver County Humane Society is urging pet owners to protect their pets from the heat. If it's hot for you, that means it's even hotter for your pet. The warning comes as Pittsburgh has 90-degree temperatures in the forecast next week. "We love summer as much as our pets, but we have a responsibility to protect them from unsafe conditions," Butler County Humane Society Executive Director Alison Yazer said in a news release. "Animals left in hot temperatures, especially enclosed spaces like cars, can develop heatstroke in as little as 15 minutes. Unfortunately, many pets don't survive it, even with veterinary intervention." During hot temperatures, it's important to give pets plenty of fresh, clean and cool water to keep them hydrated. Time outside should be limited, and if you are heading out, make sure the asphalt isn't too hot, because it can burn a pet's paws. Know the signs of overheating: excessive panting, trouble breathing, drooling and an increased heart rate. If your pet is collapsing, having a seizure or has bloody diarrhea or vomiting, then they may be experiencing a heat-related emergency. Is it illegal to leave a pet in a hot car? It's not illegal to leave your pet in a vehicle, but police officers, humane officers and animal control officers have the right to forcibly remove pets from cars if they have good-faith reason to believe the pet will suffer harm if not immediately removed. Leaving a pet in a car in dangerous conditions could lead to charges of animal cruelty, neglect or abandonment, which, in Pennsylvania, is punishable by up to seven years in jail and as much as $15,000 in fines, the humane society says. Earlier this month in Altoona, a man was charged with a felony count of animal cruelty after his dog, which was rescued from a hot truck, died on the way to the vet.
Business Wire
17-06-2025
- Business Wire
X-Atlas/Orion: Xaira Therapeutics Unveils Largest Publicly Available Genome-Wide Perturb-seq Dataset to Power Next-Generation AI for Biology
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Xaira Therapeutics today announced a significant leap forward in developing AI-driven virtual cell models with the release of 'X-Atlas/Orion,' the largest publicly available Perturb-seq atlas. This extensive dataset was made possible by Xaira's concurrently introduced 'Fix-Cryopreserve-ScRNAseq' (FiCS) Perturb-seq platform, a highly scalable technology designed for large-scale data generation. These combined advancements are poised to accelerate the development of biological foundation models and unlock new frontiers in biological discovery and therapeutic development. 'We believe this will help us better understand disease biology and discover drug targets.' The rapid progress of single cell technology has spurred the creation of foundation models aimed at deciphering complex biological processes. While these models hold immense potential for creating AI-driven virtual cells, their advancement has been hampered by the scarcity of large-scale, high-quality perturbation data. Xaira's FiCS Perturb-seq platform, which leverages the Chromium platform from 10x Genomics, delivers the sensitivity, scalability and reproducibility essential for generating high-quality perturbational data. Xaira's innovative approach solves logistical challenges associated with profiling large numbers of cells, effectively captures perturbation-induced transcriptomic changes and accurately recapitulates known biological pathways and protein complexes. The X-Atlas/Orion dataset itself comprises 8 million cells, targeting all human protein-coding genes, with deep sequencing of over 16,000 unique molecular identifiers (UMIs) per cell, allowing for the discovery of biological phenotypes from a wide range of genetic perturbations. 'This industrialized platform and the Orion dataset will empower scientists to build more predictive models of complex biology,' said Ci Chu, vice president of early discovery at Xaira and senior author of the preprint. 'We believe this will help us better understand disease biology and discover drug targets.' One of the most significant advances is Xaira's method to detect dose-dependent genetic effects, a more refined way of understanding how gene activity changes with the intensity of a given intervention. Traditionally, scientists viewed Perturb-seq gene knockdowns as an 'on' or 'off' switch. The Xaira scientists showed that the amount of single guide RNA (sgRNA) detected in each cell can be used to measure how strongly a gene is suppressed, offering a much more detailed picture of genetic function. This methodology offers a refined framework to enhance the predictive power and biological insight of future causal models by incorporating perturbation strength as a continuous variable. 'This platform provides the scale and quality needed to model how cells respond across conditions, which is a crucial step toward training the first generation of virtual cell models,' said Bo Wang, SVP and head of biomedical AI for Xaira Therapeutics. 'With this foundation, we're better equipped to uncover disease mechanisms and design smarter therapies.' This publication caps a landmark year for Xaira since its launch in April 2024. In October 2024, Dr. David Baker, Xaira co-founder, received the Nobel Prize in Chemistry alongside Drs. Demis Hassabis and John Jumper of Google DeepMind for pioneering AI-driven advancements in protein structure prediction and novel protein design. The Xaira team is working to advance these models while developing new methods that can connect the world of biological targets and engineered molecules to the human experience of disease. Access the Dataset: X-Atlas/Orion is now publicly available here: FiCS Perturb-seq and X-Atlas/Orion publication: About Xaira Therapeutics Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
